Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adoption, implementation, and evaluation of the HEARTS initiative on blood pressure outcomes: a quality improvement project in a large healthcare system in the United States.

Lancet regional health. Americas·2026
Same author

A Decade of POCUS Training in Family Medicine: Curriculum and Outcomes.

Family medicine·2026
Same author

Obesity Management: Evaluation.

FP essentials·2026
Same author

Obesity Management: Lifestyle Interventions.

FP essentials·2026
Same authorSame journal

Obesity Management: Surgical Interventions.

FP essentials·2026
Same author

Understanding Population Health Management Practices Among Family Medicine Residency Programs.

Family medicine·2025
Same journal

Skin Cancer: Management of Cutaneous Melanoma.

FP essentials·2026
Same journal

Skin Cancer: Management of Actinic Keratoses and Keratinocyte Carcinomas.

FP essentials·2026
Same journal

Skin Cancer: Diagnosis.

FP essentials·2026
Same journal

Skin Cancer: Screening and Prevention.

FP essentials·2026
Same journal

Skin Cancer.

FP essentials·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Obesity Management: Pharmacotherapy.

Morgan A Rhodes1, A Miles Scott1, Matthew Nodelman2

  • 1University of South Carolina School of Medicine; Prisma Health Family Medicine Residency Program (FMRP) in Columbia, South Carolina.

FP Essentials
|May 8, 2026
PubMed
Summary
This summary is machine-generated.

Anti-obesity medications are recommended for overweight and obese adults, especially those with comorbidities. Incretin mimetics like tirzepatide show significant weight loss, but access barriers remain.

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Related Experiment Videos

Last Updated: May 9, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Area of Science:

  • Pharmacology
  • Endocrinology
  • Public Health

Background:

  • Obesity is a complex condition requiring multifaceted treatment approaches.
  • Pharmacotherapy is an essential component of comprehensive obesity management.
  • Current FDA-approved anti-obesity drugs include centrally acting agents, lipase inhibitors, and incretin mimetics.

Purpose of the Study:

  • To review the role of anti-obesity medications in managing overweight and obesity.
  • To highlight the efficacy of newer agents, particularly incretin mimetics.
  • To discuss considerations for drug selection and persistent barriers to access.

Main Methods:

  • Literature review of current anti-obesity pharmacotherapies.
  • Analysis of clinical trial data for weight loss efficacy.
  • Discussion of individualized treatment strategies and access challenges.

Main Results:

  • Incretin mimetics, such as GLP-1 receptor agonists (semaglutide, liraglutide) and dual GIP/GLP-1 RAs (tirzepatide), offer substantial weight loss, with tirzepatide achieving >20% reduction in some cases.
  • Anti-obesity drugs are recommended as initial or first-line treatment for adults with overweight/obesity, particularly those with comorbidities or at high risk.
  • Individualized drug selection based on comorbidities, cost, and patient preference is crucial.

Conclusions:

  • Pharmacotherapy is a vital tool for obesity treatment, with incretin mimetics demonstrating significant efficacy.
  • Addressing barriers such as prescriber hesitancy, high costs, and limited insurance coverage is essential for improving patient access and outcomes.
  • Continued innovation and expanded education are critical for advancing obesity pharmacotherapy.